Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Publication · FDA Device Classification & Reporting

FDA Medical Device Classification and Adverse Event Reporting: A Systematic Overview

Classification (Class I, II, III) and adverse event reporting are two separate FDA systems with two separate regulations — 21 CFR Parts 862-892 for classification, 21 CFR Part 803 for reporting — and conflating their timelines is a common, avoidable error.

Pubrica AcademyWritten by a regulatory affairs research writer Reviewed bya medical device regulatory affairs specialist Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources10 peer-reviewed

FDA medical device classification and FDA adverse event reporting are frequently discussed together but are governed by entirely separate parts of the regulations, with separate purposes, separate timelines and separate databases. Classification determines what a manufacturer must do before a device reaches the market; adverse event reporting determines what must happen after a device is in use and an adverse event or malfunction occurs. This overview sets out both systems directly from FDA’s own primary sources, including the specific point at which a common account of these rules misstates the timeline: the 90-day advance notice requirement belongs to the 510(k) premarket notification pathway, not to premarket approval (PMA).

Learning objectives

  • How the three device classes (I, II, III) are defined by risk and what regulatory pathway attaches to each.
  • The differences between the 510(k), De Novo and PMA pathways, including which one carries the 90-day advance notice requirement.
  • How mandatory Medical Device Reporting (21 CFR Part 803) differs from voluntary MedWatch reporting, and what the Manufacturer and User Facility Device Experience (MAUDE) database contains.

Common misconceptions

  • “Premarket approval (PMA) is the pathway with a 90-day advance notice requirement.” FDA's own 510(k) guidance states that manufacturers must notify FDA "at least 90 days in advance" of marketing under the Section 510(k) premarket notification process specifically — PMA is a separate, generally more extensive review pathway reserved for most Class III devices and does not carry this same 90-day notice framing.
  • “Reporting a device problem to FDA is always voluntary.” MedWatch is FDA's voluntary reporting channel for health care professionals and consumers, but 21 CFR Part 803 separately imposes mandatory reporting obligations on device manufacturers (within 30 calendar days, or 5 working days for events requiring remedial action), importers (within 30 calendar days), and device user facilities such as hospitals (within 10 working days) — these are legally required reports, not voluntary ones.

FDA classification of medical devices

FDA sorts every medical device into Class I, II, or III based on the level of risk the device poses and the regulatory controls needed to provide "reasonable assurance of safety and effectiveness"1. Class I devices carry the lowest risk and Class III devices the highest1. Each device type's classification regulation, codified across 21 CFR Parts 862 through 892, states its class alongside its intended use and marketing requirements2.

General controls — covering establishment registration and device listing, labeling requirements, and good manufacturing practice — apply across all three classes, including devices that are otherwise exempt from premarket review2. A device that was already on the U.S. market before May 28, 1976 (a "preamendments" device) was generally classified based on an assessment of its actual risk; a device introduced after that date (a "postamendments" device) is automatically placed into Class III by default regardless of its real risk level, unless FDA reclassifies it or clears it through an alternative pathway3.

The 510(k), De Novo and premarket approval (PMA) pathways

Under Section 510(k) of the Food, Drug and Cosmetic Act, a manufacturer that must register with FDA is required to notify the agency of its intent to market a device — commonly called Premarket Notification, or PMN. FDA's own guidance states that this notification must be submitted "at least 90 days in advance" of marketing4. A 510(k) submission is required when a manufacturer plans to introduce a device commercially for the first time, or to reintroduce a device that has been significantly changed in a way that could affect safety or effectiveness (for example, a change to design, materials, energy source, manufacturing process, or indications for use)4. The process works by comparing the new device to a legally marketed device already placed into a classification category, to determine "substantial equivalence"4.

The De Novo pathway exists for novel, postamendments devices of low-to-moderate risk that have no existing predicate device to be compared against for 510(k) purposes — successful De Novo review places the device into Class I or II directly, rather than defaulting it into Class III3. Premarket Approval (PMA) is the pathway for devices that remain in Class III, typically because they present the highest risk and have no suitable predicate; it is FDA's most rigorous review pathway and, unlike the 510(k) process, is not framed around a fixed 90-day advance-notice period in FDA's guidance3.

Mandatory Medical Device Reporting under 21 CFR Part 803

Once a device is on the market, a separate regulation, 21 CFR Part 803 (Medical Device Reporting, or MDR), imposes mandatory reporting duties on three groups: device manufacturers, importers, and device user facilities (hospitals, ambulatory surgical facilities, nursing homes, and outpatient diagnostic or treatment facilities, though not physicians' offices, school nurse offices, or employee health units)5. The stated purpose of Part 803 is to help FDA detect and correct problems in a timely manner, protecting public health by helping ensure devices are not adulterated or misbranded5.

The reporting timelines differ by reporter type. Device user facilities must report within 10 working days of becoming aware of a reportable event; a death must be reported to both FDA and the manufacturer, while a serious injury goes to the manufacturer (or to FDA directly if the manufacturer is unknown)5. Importers must report within 30 calendar days5. Manufacturers must report reportable deaths, serious injuries, or malfunctions within 30 calendar days, but must report within 5 working days when an event requires remedial action to prevent an unreasonable risk of substantial harm, or when FDA has made a specific written request5. A reportable event, broadly, is one that reasonably suggests a marketed device has or may have caused or contributed to a death or serious injury, or that a device malfunctioned in a way that would likely cause death or serious injury if the malfunction recurred5.

MedWatch, the MAUDE database, and voluntary reporting

Separate from the mandatory MDR system, FDA operates MedWatch, "The FDA Safety Information and Adverse Event Reporting Program," which allows health care professionals and consumers to voluntarily report serious problems they suspect are associated with a medical product they prescribe, dispense, or use, including problems with a family member's care6. MedWatch guidance specifically encourages reporting "even if you are not sure that the product was the cause"6.

Reports gathered through both the mandatory MDR system and voluntary channels feed into the Manufacturer and User Facility Device Experience (MAUDE) database, FDA's public repository of device adverse event reports. MAUDE includes voluntary reports dating back to June 1993, user facility reports since 1991, distributor reports since 1993, and manufacturer reports since August 19967. Before public release, FDA redacts trade secrets, confidential commercial or financial information, and personal or medical information, including the identity of the original reporter, under FOIA and the Privacy Act7.

Numbers of classified device types and Class I exemptions

FDA's own classification guidance gives a concrete sense of scale behind the three-class system: the agency sorts roughly 1,700 distinct generic device types across 16 medical specialty panels, with each type assigned to Class I, II, or III based on risk.8 Within Class I specifically, about 74% of the 572 Class I device types are exempt from the 510(k) premarket notification requirement entirely, reflecting their lowest-risk status; the remaining Class I types, along with most Class II types, do require a 510(k) submission unless a specific exemption applies.8 A device's classification is determined by its intended use and indications for use as stated in its own labeling, not by its underlying technology in isolation — two devices built on similar technology can carry different classifications if their labeled intended uses differ, which is why FDA also offers a formal 513(g) Request process for a manufacturer to obtain a written classification determination rather than guessing from a generic device-type description.8

Artificial intelligence (AI)-enabled devices and postmarket safety

Both classification and adverse event reporting have had to adapt to software- and AI-based devices specifically. FDA's Digital Health Center of Excellence maintains a dedicated strategic priority on artificial intelligence and machine learning in Software as a Medical Device (SaMD), alongside published guidance on predetermined change control plans — the mechanism by which a manufacturer can pre-specify, and have FDA review in advance, how an AI-enabled device's software function is allowed to change after it is already on the market, rather than requiring a wholly new submission for every model update.9 That mechanism connects classification and adverse event reporting more tightly than for a traditional, unchanging device: a change permitted under an authorized predetermined change control plan still has to be tracked against the same Part 803 reporting obligations described above, since a post-update malfunction that meets the reportable-event definition remains reportable regardless of whether the update itself required a new premarket submission. The Medical Device Safety hub on FDA's site collects the related postmarket resources — recall notices, safety communications, and the MedSun safety network — that sit alongside MDR and MAUDE as part of the same postmarket surveillance picture this article has described.10

Key points

Key points

Classification (21 CFR Parts 862-892, with 510(k), De Novo, and PMA as the three distinct premarket pathways) and adverse event reporting (21 CFR Part 803's mandatory manufacturer/importer/user-facility reports, plus FDA's voluntary MedWatch channel feeding the public MAUDE database) are two separate regulatory systems — and the 90-day advance notice requirement belongs specifically to the 510(k) pathway, not to PMA.

Practical application

Practical application

  1. The specific pathway should be named, rather than ‘FDA approval’ in general terms. Authors should state whether a device underwent 510(k) clearance, De Novo classification or PMA approval; the three carry different evidentiary burdens and different timelines, and ‘FDA approved’ is technically correct only for PMA.
  2. The 90-day notice requirement should be attributed correctly. The 90-day advance notice before marketing is a 510(k) premarket notification requirement according to FDA’s own guidance, not a PMA requirement, and this should be verified before it is cited in a regulatory-affairs document.
  3. Classification citations should be kept separate from reporting citations. 21 CFR Parts 862-892 should be cited for classification questions and 21 CFR Part 803 for adverse-event-reporting questions; they are different regulatory parts with different compliance obligations.

Frequently asked questions

The 510(k) Premarket Notification pathway. FDA's own guidance states that a manufacturer must notify FDA "at least 90 days in advance" of marketing under Section 510(k) — this is specific to 510(k) submissions, not to PMA.

No. MedWatch is FDA's voluntary channel for health care professionals and consumers. Separately, 21 CFR Part 803 makes reporting mandatory for device manufacturers (30 calendar days, or 5 working days for events needing remedial action), importers (30 calendar days), and device user facilities such as hospitals (10 working days).

MAUDE (Manufacturer and User Facility Device Experience) is FDA's public database of device adverse event reports, drawing on both mandatory MDR submissions and voluntary MedWatch reports, with personal and confidential commercial information redacted before release under FOIA and the Privacy Act.

FDA classifies about 1,700 generic device types across 16 medical specialty panels; within Class I, about 74% of the 572 Class I device types are exempt from 510(k) premarket notification given their lowest-risk status.

No. A predetermined change control plan governs how an AI-enabled device's software function may change after authorization without a new premarket submission; any reportable death, injury, or malfunction after such an update is still subject to the same 21 CFR Part 803 mandatory reporting obligations.

References

  1. U.S. Food and Drug Administration. Overview of Medical Device Classification and Reclassification. read 10 October 2026. View on FDA.gov
  2. U.S. Food and Drug Administration. Device Classification Panels. read 10 October 2026. View on FDA.gov
  3. U.S. Food and Drug Administration. Medical Device De Novo Classification Process; related classification and reclassification guidance. read 10 October 2026. View on FDA.gov
  4. U.S. Food and Drug Administration. 510(k) Clearances / Premarket Notification 510(k) overview. read 10 October 2026. View on FDA.gov
  5. 21 CFR Part 803 — Medical Device Reporting. Code of Federal Regulations, Title 21, Volume 8. read 10 October 2026. View source
  6. U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program — Information About Reporting Adverse Events. read 10 October 2026. View on FDA.gov
  7. U.S. Food and Drug Administration. Medical Device Reporting (MDR): How to Report Medical Device Problems — Adverse Event Reporting Data Files (MAUDE). read 10 October 2026. View on FDA.gov
  8. U.S. Food and Drug Administration. Classify Your Medical Device: device classes, panel counts, and 510(k)-exempt Class I device statistics. read 10 October 2026. View on FDA.gov
  9. U.S. Food and Drug Administration. Digital Health Center of Excellence: Artificial Intelligence and Machine Learning in Software as a Medical Device. read 10 October 2026. View on FDA.gov
  10. U.S. Food and Drug Administration. Medical Device Safety (postmarket safety communications, recalls, and the MedSun network). read 10 October 2026. View on FDA.gov

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). FDA Medical Device Classification and Adverse Event Reporting: A Systematic Overview. Pubrica. https://pubrica.com/academy/systematic-review/fda-classify-medical-devices-and-how-to-report-device-problems-a-systematic-review/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

FDA classification and reporting compliance checklist

This checklist is intended to confirm that a manufacturer or researcher has correctly separated classification obligations from adverse-event-reporting obligations.

[ ] Confirmed the device's class (I, II, or III) and its governing 21 CFR Part (862-892)
[ ] Identified the correct premarket pathway (510(k), De Novo, or PMA) and its specific timeline
[ ] Verified the 90-day advance notice requirement is attributed to 510(k), not PMA
[ ] Set up mandatory MDR reporting procedures per 21 CFR Part 803 with correct timelines by reporter type
[ ] Distinguished mandatory MDR reporting from voluntary MedWatch reporting in internal documentation
[ ] For AI/ML-enabled devices, confirmed whether a predetermined change control plan applies and that MDR obligations still apply post-update
[ ] Checked FDA's Medical Device Safety hub for related recalls/communications before relying on MAUDE alone

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica's regulatory affairs writers verify every classification and adverse-event-reporting claim directly against FDA's primary guidance and the Code of Federal Regulations, correcting the type of pathway/timeline conflation this overview addresses.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Verification of device classification and adverse event reporting content against FDA primary sources

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.